(Q43064210)

13 November 2017

title

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

13 November 2017

1 reference

1 reference

Fausta Catapano

1

1 reference

13 November 2017

Afzal N Chaudhry

2

1 reference

13 November 2017

Rachel B Jones

3

1 reference

13 November 2017

Kenneth G C Smith

4

1 reference

13 November 2017

David W Jayne

5

1 reference

13 November 2017

language of work or name

English

0 references

publication date

11 May 2010

1 reference

Nephrology Dialysis Transplantation

13 November 2017

published in

1 reference

13 November 2017

volume

25

1 reference

13 November 2017

issue

11

1 reference

13 November 2017

page(s)

3586-3592

1 reference

T- and B-cell abnormalities in systemic lupus erythematosus

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Tolerability and safety of rituximab (MabThera).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFQ256

21 January 2018

Identifiers

DOI

10.1093/NDT/GFQ256

1 reference

13 November 2017

1 reference